Division of Pediatric Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Am J Hematol. 2023 Apr;98(4):620-627. doi: 10.1002/ajh.26837. Epub 2023 Feb 6.
Children with sickle cell disease (SCD) commonly experience vaso-occlusive pain episodes (VOE) due to sickling of erythrocytes, which often requires care in the emergency department. Our objective was to assess the use and impact of intranasal fentanyl for the treatment of children with SCD-VOE on discharge from the emergency department in a multicenter study. We conducted a cross-sectional study at 20 academic pediatric emergency departments in the United States and Canada. We used logistic regression to test bivariable and multivariable associations between the outcome of discharge from the emergency department and candidate variables theoretically associated with discharge. The study included 400 patients; 215 (54%) were female. The median age was 14.6 (interquartile range 9.8, 17.6) years. Nineteen percent (n = 75) received intranasal fentanyl in the emergency department. Children who received intranasal fentanyl had nearly nine-fold greater adjusted odds of discharge from the emergency department compared to those who did not (adjusted odds ratio 8.99, 95% CI 2.81-30.56, p < .001). The rapid onset of action and ease of delivery without intravenous access offered by intranasal fentanyl make it a feasible initial parenteral analgesic in the treatment of children with SCD presenting with VOE in the acute-care setting. Further study is needed to determine potential causality of the association between intranasal fentanyl and discharge from the emergency department observed in this multicenter study.
患有镰状细胞病(SCD)的儿童经常因红细胞镰状化而经历血管阻塞性疼痛发作(VOE),这通常需要在急诊部门进行护理。我们的目的是评估在一项多中心研究中,鼻内芬太尼在治疗 SCD-VOE 儿童从急诊部门出院方面的使用情况和影响。我们在美国和加拿大的 20 个学术儿科急诊部门进行了一项横断面研究。我们使用逻辑回归测试了与出院结局相关的候选变量之间的双变量和多变量关联,这些候选变量在理论上与出院相关。该研究包括 400 名患者;215 名(54%)为女性。中位年龄为 14.6 岁(四分位距 9.8-17.6)。19%(n=75)在急诊室接受了鼻内芬太尼治疗。与未接受鼻内芬太尼治疗的儿童相比,接受鼻内芬太尼治疗的儿童从急诊部门出院的调整后几率几乎高出九倍(调整后优势比 8.99,95%CI 2.81-30.56,p<0.001)。鼻内芬太尼具有起效迅速、无需静脉通路即可给药的优势,使其成为治疗急性护理中出现 VOE 的 SCD 儿童的可行初始肠外镇痛剂。需要进一步研究以确定在这项多中心研究中观察到的鼻内芬太尼与从急诊部门出院之间的关联的潜在因果关系。